In this study, we chose PCSK9, the most documented regulator of lipid metabolism in recent years37–39, as the key factor to be investigated in relation to the underlying mechanism of olanzapine-induced NAFLD. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.